Laurent Fischer
CIK 1379344 · CEO, PRESIDENT AND DIRECTOR · last filed 2026-06-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.07M
Companies
6
Total Filings
49
Lifetime Open-Market Net
$899.9K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MIRM | Director | 10,727 | $100.00 | $1.07M | $69.0K | 10 | 2026-06-17 |
| ATAI | Director | — | $7.25 | — | $0 | 3 | 2026-06-08 |
| Adverum Biotechnologies, Inc. (ADVM) Delisted | CEO, PRESIDENT AND DIRECTOR | 522,666 | $4.36 | $2.28M | $830.9K | 21 | 2025-12-10 |
| CTI BIOPHARMA CORP (CTIC) Delisted | Director | — | $9.09 | — | $0 | 8 | 2023-06-26 |
| Tobira Therapeutics, Inc. (TBRA) Delisted | Chief Executive Officer | — | — | — | $0 | 3 | 2016-01-14 |
| PANACOS PHARMACEUTICALS, INC. (PANC) Delisted | Director | — | — | — | $0 | 3 | 2008-06-30 |
Recent Filings · Page 3 of 5
49 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-09-21 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Sell (S) | −41,082 | -$43.9K | EDGAR |
| 2022-09-16 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-06 | MIRM | Grant (A) | — | $0 | EDGAR |
| 2022-04-22 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Buy (P) | +25,000 | $27.8K | EDGAR |
| 2022-03-17 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-03-11 | CTI BIOPHARMA CORP (CTIC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-12-10 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Buy (P) | +25,000 | $45.6K | EDGAR |
| 2021-08-10 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Grant (A) | +680,000 | $0 | EDGAR |
| 2021-06-08 | MIRM | Grant (A) | — | $0 | EDGAR |
| 2021-03-24 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Buy (P) | +10,000 | $98.8K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.